Adiponectin: mechanistic insights and clinical implications
- First Online:
- Cite this article as:
- Turer, A.T. & Scherer, P.E. Diabetologia (2012) 55: 2319. doi:10.1007/s00125-012-2598-x
Adiponectin is an adipocyte-derived secretory protein that has been very widely studied over the past 15 years. A multitude of different functions have been attributed to this adipokine. It has been characterised in vitro at the level of tissue culture systems and in vivo through genetic manipulation of rodent models. It is also widely accepted as a biomarker in clinical studies. Originating in adipose tissue, generally positive metabolic effects have been attributed to adiponectin. In this review, we briefly discuss the key characteristics of this interesting but very complex molecule, highlight recent results in the context of its mechanism of action and summarise some of the key epidemiological data that helped establish adiponectin as a robust biomarker for insulin sensitivity, cardiovascular disease and many additional disease phenomena.
AMP-activated protein kinase
Adiponectin is a 30 kDa protein with a globular C-terminal domain and a collagenous N-terminal domain . The collagen domain allows adiponectin to form trimers, hexamers, and higher order complexes prior to being secreted. A cysteine residue (Cys39 in the mouse) in the collagenous stalk is a critical mediator of higher order complexes , which may represent the most biologically active forms of the protein [7, 8]. Adiponectin is structurally related to both C1q and TNFα, which are prototypical members of a growing family of paralogues known as C1q/TNF-related proteins (‘CTRPs’) .
Adiponectin’s actions are mediated through a number of receptors, such as adiponectin receptors 1 and 2 (ADIPOR1 and ADIPOR2) . These receptors are predicted to have seven transmembrane portions but are functionally distinct from G-protein-coupled receptors, particularly as they have the opposite polarity (i.e. N-terminus is facing the intracellular compartment). Single- and double-knockout mice for the adiponectin receptors suggest a significant amount of functional redundancy between them . Although relative ratios of ADIPOR1 and ADIPOR2 may vary from tissue to tissue, in general, both are fairly ubiquitously expressed. An additional cell surface molecule with significant affinity for adiponectin, referred to as T-cadherin, has been identified . Although it binds adiponectin, it is not a signalling receptor per se, as it lacks an intracellular signalling domain. Nevertheless, T-cadherin is required for adiponectin to exert its full cardioprotective potential .
Other pathways may exist. There is early evidence for additional, as-yet-unidentified adiponectin receptors that may mediate improvements in insulin sensitivity . Also, in some cell types, the adaptor protein APPL1 has been implicated as a downstream mediator of adiponectin signalling through its interaction with the adiponectin receptors .
Secretion and clearance
Adiponectin is an adipose-specific secretory protein and its transcript is abundant in the adipocyte. It is constitutively produced and constitutes approximately 0.01–0.05% of plasma protein (usual range, 2–20 μg/ml), so it is a relatively abundant plasma factor. Adiponectin is a very stable protein in the circulation, with minimal degradation observed while circulating , but it has a surprisingly short plasma half-life of ~45–75 min, depending on the complex and the conditions . The liver is the primary site of adiponectin clearance from the circulation , but other cell types also bind adiponectin quite avidly, in particular, pancreatic beta cells as well as some cell types in the heart and kidney.
Adiponectin promotes beta cell function and survival
The adiponectin receptors ADIPOR1 and ADIPOR2 are expressed in pancreatic islets, specifically, on the beta cells [20–22]. Although both ADIPOR1 and ADIPOR2 are present, ADIPOR1 is the predominant form, at least in the mouse. Not only is the receptor expressed here, but exogenously administered recombinant adiponectin given to adiponectin-null mice avidly binds to beta cells, suggesting that circulating adiponectin directly targets this tissue.
Adiponectin may act to increase glucose-mediated insulin secretion and transcription of insulin and related gene products . While the data are not clear on the effect of adiponectin on insulin release under conditions of normal insulin sensitivity [22, 24], it does, however, appear to increase glucose-mediated insulin secretion in high-fat diet-fed mice (i.e. under insulin-resistant conditions) .
Several studies have demonstrated that adiponectin has anti-apoptotic effects on beta cells, both in cell culture and islet preparations [23, 25–27]. This effect in the pancreas does not appear to be mediated through activation of AMP-activated protein kinase (AMPK), but may be, at least in part, due to activation of other pro-survival kinases, such as extracellular signal-regulated kinases 1 and 2 (ERK1/2) and Akt [23, 26].
Cardioprotective and renal effects of adiponectin
The potent correlations and strong predictive value of adiponectin measurements for the future development of cardiovascular disease have been appreciated for many years. In a 2004 landmark study, Pischon and colleagues established in a very large cohort that high plasma adiponectin concentrations are associated with a lower risk of myocardial infarction in men . Potent positive correlations with HDL-cholesterol can be seen, and in preclinical studies the Walsh group elegantly established potent effects of recombinant adiponectin on cardiomyocyte survival in the context of ischaemia/reperfusion studies . Based on our in vitro and in vivo data, these effects may be, at least in part, explained on the basis of the ceramide-lowering effects of adiponectin . It remains an unsolved issue why end-stage cardiovascular disease, in contrast to early stages, displays a strong positive correlation between all-cause and cardiovascular mortality and high levels of adiponectin . A similar situation prevails in the kidney. Low adiponectin correlates with albuminuria in both mice and humans [31, 32]. Lack of adiponectin has been linked to increased podocyte injury and albuminuria in adiponectin gene knockout (Adipoq−/−) mouse models, with adiponectin therapies potentially reversing some renal dysfunction [33, 34]. Similar to the observations in cardiovascular disease, these positive adiponectin effects on renal physiology are in contrast to the elevated levels observed in both children and adults with chronic kidney disease, whose adiponectin levels are positively correlated with proteinuria [32, 35]. Similar to end-stage cardiovascular disease, it is not known which mechanisms lead to this upregulation, particularly since adiponectin is not cleared through the kidney except in cases of severe proteinuria . In both cases, however, we assume that this reflects a compensatory upregulation of adiponectin production, although it is possible that in the end stages of these conditions, the low fat mass associated with cachexia begins to significantly confound the relationship between adiponectin and survival. At the current time, the reasons for these unexpected findings are unclear and will need to be elucidated by further studies.
Adiponectin improves peripheral insulin sensitivity
Adiponectin and skeletal muscle
Being a major source of systemic glucose, skeletal muscle plays a key role in insulin sensitivity. Not surprisingly, therefore, there has been considerable attention paid to the possible metabolic effects adiponectin has on this tissue.
ADIPOR1 is the predominant adiponectin receptor found in skeletal muscle [10, 37, 38]. Most studies have utilised binding with globular adiponectin, which appears to have higher binding and more biological activity in skeletal muscle than the full-length form [39–41]. The in vivo physiological significance of the globular form remains quite unclear, however, as the vast majority, if not all, circulating adiponectin exists in full-length, multimeric complexes.
Bearing this important limitation in mind, globular adiponectin appears to act, at least in part, through AMPK (and, subsequently, by inhibiting acetyl-CoA carboxylase) [39, 40, 42] and PPARα [11, 43] to exert its metabolic effects in muscle. AMPK phosphorylation in C2C12 myotubes can be prevented by ceramidase inhibition, again supporting a role for sphingolipid metabolism in adiponectin signalling in this tissue . Adiponectin binding results in an increase in glucose uptake (via GLUT4 translocation) and non-oxidative glycolysis, while at the same time reducing intramyocellular triacylglycerol content and promoting fatty acid oxidation [40–44]. Furthermore, adiponectin has effects on mitochondrial number and oxidative fibre types [42, 45].
In the diseased state, the effects of adiponectin on skeletal muscle are dampened. The binding of both globular and full-length adiponectin is decreased in the obese, insulin-resistant ob/ob mouse, which may be due to a lower adiponectin receptor density . While human studies do not demonstrate altered ADIPOR1/ADIPOR2 mRNA levels associated with insulin-resistant states [37, 38], cultured myotubes from obese patients with and without diabetes demonstrate impaired adiponectin-stimulated AMPK phosphorylation and fatty acid oxidation . This suggests impaired adiponectin action downstream of the adiponectin receptor. Since these effects can be seen in in vitro patient samples, they are independent of other potentially confounding circulating hormonal factors (e.g. insulin).
Although there are a considerable number of papers dedicated to adiponectin action in muscle, the authors remain somewhat sceptical of the relevance of the published data on the physiology of this protein in vivo. The vast majority of papers either focus on in vitro or in vivo studies predominantly performed with globular adiponectin. Can the relatively large adiponectin complexes in vivo actually effectively cross the endothelium? Muscle does not seem to be a major target of labelled adiponectin injected into mice . Neither transgenic mice overexpressing Adipoq nor Adipoq-null mice injected with recombinant adiponectin appear to have a phenotype in muscle when carefully clamped. Rather, the major differences are consistently found at the level of the liver in all these models [47–49].
Adiponectin and the liver
Adiponectin has several effects on the liver. One of the most prominent of these is suppression of hepatic glucose output, lowering systemic glucose levels. Adiponectin acts to sensitise hepatocytes to the effects of insulin, such that glucose production is significantly suppressed for any given dose of insulin in the presence of physiological doses of adiponectin . Adiponectin acts to suppress the expression [40, 50, 51] and activity  of key regulators in gluconeogenesis, such as phosphoenolpyruvate carboxykinase and glucose-6-phosphatase. As mentioned above, murine euglycaemic clamp experiments have shown no difference in rates of glucose disappearance, glycolysis or glycogen synthesis in the presence or absence of intravenous adiponectin infusion , again highlighting adiponectin’s main effect, which is to lower blood sugar by suppressing hepatic glucose output rather than disposal.
Adiponectin also acts on fatty acid metabolism in the liver, which has secondary effects on circulating levels of triacylglycerol and NEFA. Even moderate overproduction of adiponectin in transgenic mice leads to substantial protection from hepatic steatosis in the setting of obesity  or high-fat feeding , while the Adipor1/Adipor2 double-knockout mouse tends to accumulate increased liver fat . Similarly, studies in humans have consistently shown an association between low adiponectin levels and the presence and degree of liver fat . Transgenic mice overexpressing Adipoq show reduced lipogenic activity at the level of the liver , but may be predominantly protected as a result of a healthy, non-inflamed expansion of adipose tissue that can readily accommodate any excess lipids [52, 53].
Increases in the phosphorylation state of the insulin receptor, as well as downstream mediators in the insulin pathway (e.g. Akt, glycogen synthase kinase 3β), are seen with modest overproduction of adiponectin and in part mediate its effects on hepatic insulin sensitivity . There are other mechanisms at play beyond sensitisation to insulin. AMPK activation, somewhere downstream from the adiponectin receptor, has been recognised as a mechanism of adiponectin action in the liver. It has become increasingly clear in recent years, however, that many of this hormone’s effects are independent of AMPK. Liver-specific deletion of liver kinase B1 (LKB1), the major upstream activator of AMPK, blunts, but does not abolish, adiponectin’s ability to decrease serum glucose concentrations by reducing hepatic glucose output or gluconeogenic gene expression . This suggests both an LBK1/AMPK-dependent and -independent pathway of adiponectin action on the liver. Importantly, adiponectin has also been shown to lower hepatic ceramide content independently of LBK1/AMPK, supporting the key role for sphingolipid metabolism and highlighting the relevance of the sphingolipid pathway in the adiponectin-mediated effects on the liver . Overexpression of AdipoR1 and AdipoR2 in the liver has been shown to significantly increase hepatic ceramidase activity, lower high-fat diet-induced hepatic ceramide accumulation and improve insulin resistance.
Adiponectin has local effects on adipose tissue
Adipocytes are known to express the adiponectin receptors (ADIPOR1>R2) . This finding suggests that adiponectin is able to act locally in an autocrine or paracrine fashion to influence adipose tissue function.
One of the most striking effects of adiponectin’s effect on adipose tissue is seen in the Adipoq-overexpressing ob/ob mouse. This mouse displays greater adiposity than the ob/ob mouse, with the excess weight accounted for by a greater subcutaneous fat mass (while the intra-abdominal and hepatic fat matched that in wild-type mice) . Histological examination has shown that the expanded adipose tissue consists of a larger number of adipocytes with a significantly lower average cell size compared with the lipid-engorged adipocytes seen on the ob/ob background. Furthermore, mRNA levels of several key genes involved in lipid metabolism, including Pparg2 and Pgc1a, are upregulated in the white adipose tissue of these mice, suggesting a generalised improvement in lipid metabolism [52, 53].
Concurrently, overexpression of Adipoq leads to decreased infiltration of macrophages into adipose tissue  and adiponectin acts locally on adipose tissue to suppress the release of a number of pro-inflammatory cytokines (e.g. TNFα, IL-6) from adipocytes and surrounding stromal vascular cells [52, 57–60]. This demonstrates the complex interplay between local (e.g. adipose tissue) and systemic inflammation.
Adiponectin has systemic anti-inflammatory effects
Unquestionably, adiponectin exerts important effects on local inflammation in adipose tissue. However, there are significant anti-inflammatory properties of adiponectin that extend beyond this microenvironment. Insofar as systemic inflammation may promote insulin-resistance, these effects are relevant.
Adiponectin suppresses the growth and proliferation of bone marrow-derived granulocyte and macrophage progenitors while not affecting other haematopoietic cell lines . In addition, inflammatory functions in macrophages are affected: phagocytic activity is inhibited in human macrophages incubated with adiponectin , as is the release of pro-inflammatory cytokines [61, 62]. Lipopolysaccharide-stimulated TNFα and IL-6 release from macrophages is inhibited through decreased nuclear factor-κB translocation into the nucleus [59, 62]. Also, production of the anti-inflammatory cytokine, IL-10, is increased [60, 63, 64]. Conversely, the macrophages from adiponectin-null mice display an activated phenotype, with higher levels of TNFα, MCP-1 and IL-6 production than macrophages from wild-type mice. The increases in these cytokines can be reversed by exogenous administration of recombinant adiponectin . Collectively, these data suggest that adiponectin promotes the polarisation of macrophages towards an M2 (i.e. anti-inflammatory) phenotype.
Adiponectin is a key mediator of systemic insulin sensitivity and glucose homeostasis. These effects are achieved by a diverse set of effects on several important targets, including the liver, pancreas, cardiac myocytes and the immune system, and even the adipose tissue itself. The main metabolic effects of adiponectin are to suppress hepatic glucose output while suppressing inflammatory responses in many other cell types, including macrophages. Moreover, through its action on the sphingolipid pathways, adiponectin exerts potent anti-apoptotic activities that have been documented particularly for beta cells and cardiac myocytes .
Despite the tremendous interest in adiponectin and a meteoric rise in the number of publications on this protein, there remain several key areas. How relevant are the actions in the brain? Adiponectin can easily be detected in cerebrospinal fluid , and has potent central effects pharmacologically to decrease body weight and increase energy expenditure [70, 71]. Much still remains to be investigated in this area. Additional questions arise regarding signal transduction distal to the adiponectin receptor. Although traditionally the mechanism has been attributed to AMPK phosphorylation, how this activation occurs in relation to the activation of cell surface receptors is unclear. Furthermore, recent evidence has suggested that many adiponectin-mediated effects are independent of the AMPK pathway. Attention has turned to the role of ceramide catabolism as the intracellular mediator of the effects of adiponectin. There is still room for additional mechanisms of action—and hopefully the next couple of years will yield a more complete picture of how this protein functions and why the adipocyte critically depends on releasing this hormone at relatively high levels with a rather short resident time in the plasma.
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.
ATT and PES contributed to the design and drafting of this article. Both authors approved the final version of this manuscript.